SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

被引:0
|
作者
Schmidt, Timothy [1 ]
Gahvari, Zhubin [1 ]
Callander, Natalie S. [1 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Hematol Med Oncol & Palliat Care, Madison, WI USA
关键词
MGUS; MM; Risk stratification; Screening; SMM; INDEPENDENT RISK-FACTOR; LIGHT-CHAIN RATIO; MASS-SPECTROMETRY; BONE-MARROW; PROGRESSION; MGUS; LENALIDOMIDE; PREVALENCE; ABNORMALITIES; POPULATION;
D O I
10.1016/j.clml.2024.03.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Monoclonal proteins are common, with a prevalence in the United States around 5% and the incidence increases with age. Although most patients are asymptomatic, the vast majority of cases are caused by a clonal plasma cell disorder. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic precursor conditions with variable risk of progression to multiple myeloma (MM). In recent years, significant progress has been made to better understand the factors that lead to the development of symptoms and progression to myeloma. In this review, we summarize the current diagnosis treatment guidelines for MGUS and SMM and highlight recent advances that underscore a shifting paradigm in the evaluation and management of plasma cell precursor conditions.
引用
收藏
页码:653 / 664
页数:12
相关论文
共 50 条
  • [21] Pathogenesis of Monoclonal Gammopathy of Undetermined Significance and Progression to Multiple Myeloma
    Zingone, Adriana
    Kuehl, W. Michael
    SEMINARS IN HEMATOLOGY, 2011, 48 (01) : 4 - 12
  • [22] Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
    Kyle, R. A.
    Durie, B. G. M.
    Rajkumar, S. V.
    Landgren, O.
    Blade, J.
    Merlini, G.
    Kroeger, N.
    Einsele, H.
    Vesole, D. H.
    Dimopoulos, M.
    San Miguel, J.
    Avet-Loiseau, H.
    Hajek, R.
    Chen, W. M.
    Anderson, K. C.
    Ludwig, H.
    Sonneveld, P.
    Pavlovsky, S.
    Palumbo, A.
    Richardson, P. G.
    Barlogie, B.
    Greipp, P.
    Vescio, R.
    Turesson, I.
    Westin, J.
    Boccadoro, M.
    LEUKEMIA, 2010, 24 (06) : 1121 - 1127
  • [23] Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance
    Piechotta, Vanessa
    Skoetz, Nicole
    Engelhardt, Monika
    Einsele, Hermann
    Goldschmidt, Hartmut
    Scheid, Christof
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2022, 119 (14): : 253 - +
  • [24] Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies
    Korde, Neha
    Kristinsson, Sigurdur Y.
    Landgren, Ola
    BLOOD, 2011, 117 (21) : 5573 - 5581
  • [25] Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma
    Mailankody, Sham
    Mena, Esther
    Yuan, Constance M.
    Balakumaran, Arun
    Kuehl, W. Michael
    Landgren, Ola
    LEUKEMIA & LYMPHOMA, 2010, 51 (12) : 2159 - 2170
  • [26] Monoclonal gammopathy of undetermined significance: to screen or not to screen for multiple myeloma?
    Go, Ronald S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (04) : 620 - 621
  • [27] Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults
    Guerard, Emily J.
    Tuchman, Sascha A.
    CLINICS IN GERIATRIC MEDICINE, 2016, 32 (01) : 191 - +
  • [28] The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma
    Sigurdardottir, Elin Edda
    Turesson, Ingemar
    Lund, Sigrun Helga
    Lindqvist, Ebba K.
    Mailankody, Sham
    Korde, Neha
    Bjorkholm, Magnus
    Landgren, Ola
    Kristinsson, Sigurdur Y.
    JAMA ONCOLOGY, 2015, 1 (02) : 168 - 174
  • [29] Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance
    Nielsen, Thoger
    Kristensen, Soren Risom
    Gregersen, Henrik
    Teodorescu, Elena Manuela
    Pedersen, Shona
    THROMBOSIS RESEARCH, 2021, 202 : 108 - 118
  • [30] Monoclonal gammopathy of undetermined significance: to screen or not to screen for multiple myeloma? - response
    Bird, Jenny
    Behrens, Judith
    Drayson, Mark T.
    Turesson, Ingemar
    Westin, Jan
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (04) : 621 - 623